Published in Int J Radiat Oncol Biol Phys on March 01, 2003
Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys (2010) 3.83
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2009) 1.71
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys (2012) 1.70
Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis. J Radiat Res (2014) 0.87
Prostate bed motion during intensity-modulated radiotherapy treatment. Int J Radiat Oncol Biol Phys (2012) 0.83
A dosimetric analysis of volumetric-modulated arc radiotherapy with jaw width restriction vs 7 field intensity-modulated radiotherapy for definitive treatment of cervical cancer. Br J Radiol (2014) 0.81
Modeling plan-related clinical complications using machine learning tools in a multiplan IMRT framework. Int J Radiat Oncol Biol Phys (2009) 0.79
Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles. J Med Radiat Sci (2016) 0.75
Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst (2004) 4.07
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2004) 3.54
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol (2003) 2.65
Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol (2012) 2.46
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol (2005) 2.18
Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol (2005) 2.14
Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study. Int J Radiat Oncol Biol Phys (2013) 2.04
Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol (2003) 1.97
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol (2005) 1.88
Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer (2009) 1.82
Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol (2009) 1.62
First human Cerenkography. J Biomed Opt (2013) 1.53
Gamma Knife radiosurgery for vestibular schwannoma: clinical results at long-term follow-up in a series of 379 patients. J Neurosurg (2014) 1.45
Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. Int J Radiat Oncol Biol Phys (2004) 1.43
Multispectral Cerenkov luminescence tomography for small animal optical imaging. Opt Express (2011) 1.42
Adjuvant radiotherapy for malignant pleural mesothelioma: challenges and pitfalls. Radiother Oncol (2012) 1.38
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst (2006) 1.38
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res (2011) 1.35
In vivo ¹⁸F-FDG tumour uptake measurements in small animals using Cerenkov radiation. Eur J Nucl Med Mol Imaging (2010) 1.28
IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol (2009) 1.27
Prostatic stromal tumor with fatal outcome in a young man: histopathological and immunohistochemical case presentation. Rare Tumors (2010) 1.26
Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys (2007) 1.23
Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. Int J Radiat Oncol Biol Phys (2008) 1.21
Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer (2002) 1.20
Inflammatory pseudotumor of mediastinum treated with tomotherapy and monitored with FDG-PET/CT: case report and literature review. Tumori (2010) 1.13
A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer (2004) 1.09
Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer (2004) 1.08
Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer. Radiother Oncol (2006) 1.08
Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys (2008) 1.07
Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. Radiother Oncol (2009) 1.06
Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program. Clin Cancer Res (2008) 1.04
Predictors of PEG dependence after IMRT±chemotherapy for oropharyngeal cancer. Radiother Oncol (2013) 1.03
Target delineation in post-operative radiotherapy of brain gliomas: interobserver variability and impact of image registration of MR(pre-operative) images on treatment planning CT scans. Radiother Oncol (2005) 1.03
The impact of contouring uncertainty on rectal 3D dose-volume data: results of a dummy run in a multicenter trial (AIROPROS01-02). Int J Radiat Oncol Biol Phys (2003) 1.03
Weekly dose-volume parameters of mucosa and constrictor muscles predict the use of percutaneous endoscopic gastrostomy during exclusive intensity-modulated radiotherapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys (2010) 1.03
Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol (2002) 1.02
Treatment planning comparison between conformal radiotherapy and helical tomotherapy in the case of locally advanced-stage NSCLC. Radiother Oncol (2008) 1.00
Dose-volume and biological-model based comparison between helical tomotherapy and (inverse-planned) IMAT for prostate tumours. Radiother Oncol (2008) 1.00
Rectal and bladder motion during conformal radiotherapy after radical prostatectomy. Radiother Oncol (2004) 0.98
Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy. Int J Radiat Oncol Biol Phys (2008) 0.96
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res (2004) 0.96
Agreement criteria between expected and measured field fluences in IMRT of head and neck cancer: the importance and use of the gamma histograms statistical analysis. Radiother Oncol (2007) 0.96
Dosimetric predictors of laryngeal edema. Int J Radiat Oncol Biol Phys (2007) 0.96
Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial. J Thorac Oncol (2008) 0.95
Comparing 3DCRT and inversely optimized IMRT planning for head and neck cancer: equivalence between step-and-shoot and sliding window techniques. Radiother Oncol (2005) 0.94
Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: a treatment planning comparison. Radiother Oncol (2010) 0.93
A two-variable linear model of parotid shrinkage during IMRT for head and neck cancer. Radiother Oncol (2010) 0.92
Primary pulmonary meningioma: report of a case and review of the literature. Lung Cancer (2008) 0.92
Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group. Lung Cancer (2010) 0.92
Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients. Int J Radiat Oncol Biol Phys (2010) 0.91
Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. J Oncol (2009) 0.91
Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys (2009) 0.89
Treatment approaches for primary CNS lymphomas. Expert Opin Pharmacother (2010) 0.89
NTCP modeling of subacute/late laryngeal edema scored by fiberoptic examination. Int J Radiat Oncol Biol Phys (2009) 0.89
Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose-volume histograms and normal tissue complication probability. Radiother Oncol (2002) 0.89
Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Cancer (2007) 0.89
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer. Anticancer Res (2010) 0.87
Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation. Int J Radiat Oncol Biol Phys (2002) 0.87
FDG PET/CT metabolic tumour volume in small-cell lung cancer: better staging and prognostic stratification for an improved therapeutic strategy. Eur J Nucl Med Mol Imaging (2012) 0.87
Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys (2011) 0.87
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Eur J Cancer (2013) 0.87
PET-guided dose escalation tomotherapy in malignant pleural mesothelioma. Strahlenther Onkol (2011) 0.86
Simultaneous tumour dose escalation and liver sparing in Stereotactic Body Radiation Therapy (SBRT) for liver tumours due to CTV-to-PTV margin reduction. Radiother Oncol (2008) 0.86
Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis. Int J Radiat Oncol Biol Phys (2010) 0.86
Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues. Cancer (2009) 0.86
Remission of refractory neurosarcoidosis treated with brain radiotherapy: a case report and a literature review. Neurologist (2008) 0.86
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer (2010) 0.85
Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. Radiother Oncol (2011) 0.85